Joanne Xiu: Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals
Joanne Xiu, Vice President, Clinical and Translational Research at Caris Life Sciences, posted on LinkedIn about recent paper she and colleagues co-authored, titled “Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals” published on Nature Communications.
Authors: George W. Sledge Jr., Takayuki Yoshino, Joanne Xiu, Anthony Helmstetter, Jennifer R. Ribeiro, Sergey Klimov, Brady Gilg, JJ Gao, Jeff Elton, Matthew J. Oberley, Milan Radovich, Jim Abraham and David Spetzler
“In light of the increase in Tissue-Agnostic approvals by the FDA for cancer therapy, an extensive analysis of a vast real-world database at Caris Life Sciences reveals important clinical insights and highlights the transformative power of real-world data.
The research uncovered the potential to expand Tissue-agnostic approval for drugs of the same class, and unveiled important variation among tumor types for existing approvals; all these insights were made possible only through the extensive real-world dataset.”
Matthew Oberley, Chief Clinical Officer and Senior Vice President at Caris Life Sciences, shared this post on LinkedIn, adding:
“A concerning finding from this excellent study utilizing RWE from Caris Life Sciences and ConcertAI: Less than half of patients with pathogenic NTRK fusions get highly efficacious targeted therapy with NTRK inhibitors – I am concerned that Oncologists are not always seeing the results from molecular profiling before choosing a therapeutic pathway for their patients.
This observation supports findings of NTRKi underutilization noted previously in a survey of US oncologists.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023